First New York Securities’s Cardiff Oncology CRDF Stock Holding History

First New York Securities’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-515	Closed	-$266K	–	293
2013 Q3	$266K	Buy	515 +346	+205%	+$197K	0.11%	154
2013 Q2	$85K	Buy	+169	New	+$76.4K	0.03%	256

Other funds holding CRDF

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

First New York Securities's CRDF Position: Q4 2013 in Review

First New York Securities sold out of Cardiff Oncology (CRDF) in Q4 2013, closing a stake of 515 shares — an estimated $266K sold.

First New York Securities first reported a position in CRDF in Q2 2013 and held it in 2 quarters. The position peaked at $266K in Q3 2013. 26 funds tracked by Wall St. Rank hold CRDF as of Q4 2013.

First New York Securities reported no remaining Cardiff Oncology position as of Q4 2013 after selling out during the quarter.
First New York Securities sold 515 Cardiff Oncology shares in Q4 2013, an estimated $266K.
First New York Securities first reported a position in Cardiff Oncology in Q2 2013 and held it in 2 quarters.
First New York Securities's Cardiff Oncology position peaked at $266K in Q3 2013.
26 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2013.

Based on First New York Securities's 13F filing for Q4 2013, filed 12 Feb 2014.